Company FinancialsABBV's recent $15bn bond sale to fund its acquisitions underscores a robust financial strategy, bolstering investor trust in the company's ability to successfully complete the CERE transaction.
Drug ApprovalCERE announced positive Phase 3 TEMPO-3 study data for tavapadon, a treatment for Parkinson's disease, meeting its primary endpoint and showing a significant increase in 'on' time without troublesome dyskinesia.
Mergers And AcquisitionsThe proposed acquisition of CERE by AbbVie is expected to enhance shareholder value as it progresses towards a mid-2024 closure, reflecting the strength and confidence in the strategic merger.